Key result
In simulated severe thrombocytopenia (where thrombin potential was reduced by 60-70%), rFVIIa accelerated thrombin generation and platelet activation, and normalized clot formation velocity.
Why the study?
Does recombinant factor VIIa improve thrombin generation and clot formation in human plasma with low platelet counts?
Population
Human plasma samples with platelet counts ranging from 5 x 10(9)/l to 150 x 10(9)/l
Comparison
Recombinant factor VIIa (rFVIIa) 1 micro g/ml vs Buffer
Design
Preclinical
Authors
Loading...
Supports rFVIIa mechanism in thrombocytopenia models; leaves open human efficacy.
Does recombinant factor VIIa improve thrombin generation and clot formation in human plasma with low platelet counts?
In an in vitro model of severe thrombocytopenia, rFVIIa accelerates thrombin generation and clot formation, providing insight into its hemostatic mechanism.
Chakroun et al. (2004) studied Severe thrombocytopenia. Recombinant factor VIIa (rFVIIa) vs. Buffer was evaluated on Thrombin generation, platelet activation and clot formation. In simulated severe thrombocytopenia (where thrombin potential was reduced by 60-70%), rFVIIa accelerated thrombin generation and platelet activation, and normalized clot formation velocity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: